Drug intelligence / Profile preview

docetaxel + gemcitabine + paclitaxel + pemetrexed

Development stage
Unknown
Lead developer
Sanofi
Modality
Small Molecules
Administration
Intravenous
01

Overview

This is a combination of four chemotherapeutic agents with different mechanisms of action. Docetaxel is a taxane that inhibits microtubule disassembly. Gemcitabine is a nucleoside analog that inhibits DNA synthesis. Paclitaxel is another taxane that stabilizes microtubules. Pemetrexed is a folate analog that inhibits multiple enzymes involved in folate metabolism and DNA synthesis. Each of these drugs has established efficacy in various cancers, particularly non-small cell lung cancer (NSCLC). While these drugs have been studied in various two-drug combinations, there is limited information about all four being used together as a single regimen.

02

Targets

TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)GART (GAR transformylase)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))EGFR T790M (Epidermal growth factor receptor T790M mutant)DNA polymerase family

Beyond the preview

Go deeper on docetaxel + gemcitabine + paclitaxel + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + gemcitabine + paclitaxel + pemetrexed.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call